Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

U.S. stock futures point lower after a volatile week of trading and President Donald Trump's comments from a weekend ...

Stock futures fell again Monday, after the S&P 500 had its worst week in months amid fears about President Donald Trump's tariff policy. Mark Carney won the race to replace Justin Trudeau as Canada's ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and ...

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...